Cost effective treatment of age related macular degeneration

A British study is calling for the public funding of supplements to treat age-related eye disease following investigations into the cost-effectiveness of treatment. According to the study, age-related macular degeneration (AMD) remains the leading cause of blindness and visual impairment in the Western world despite the introduction of anti-vascular endothelial growth factor (anti-VEGF) and is set to increase in incidence with the ageing population.

To continue reading this article, please Log In or Sign Up for access.